Complex analysis of cyclin D1 expression in mantle cell lymphoma: two cyclin D1-negative cases detected
- L Stefancikova1,2,
- M Moulis1,3,
- P Fabian4,
- I Falkova1,
- I Vasova5,
- L Kren1,
- J Macak1,
- J Smardova1,2,3
- 1Department of Pathology, University Hospital Brno. Jihlavska 20, 625 00 Brno, Czech Republic
- 2Department of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska 2, 611 37 Brno, Czech Republic
- 3Faculty of Medicine, Masaryk University, Komenskeho namesti 2, 662 43 Brno, Czech Republic
- 4Department of Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
- 5Department of Hematooncology, University Hospital Brno. Jihlavska 20, 625 00 Brno, Czech Republic
- Correspondence to Dr J Smardova, Department of Pathology, University Hospital, Jihlavska 20, 625 00 Brno, Czech Republic; janasmarda{at}seznam.cz
- Accepted 17 March 2009
Abstract
Background and Aim: The cytogenetic and diagnostic hallmark of mantle cell lymphoma (MCL) is translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1. Cyclin D1 expression was analysed in 32 cases of MCL.
Methods: The t(11;14) translocation was detected by fluorescence in situ hybridisation, level of cyclin D1 mRNA by competitive RT-PCR, and level of cyclin D1 and D2 proteins by immunohistochemistry and/or immunoblotting.
Results: In 30 cases, the presence of translocation t(11;14), a high level of cyclin D1 mRNA, and a high level of the cyclin D1 protein were confirmed. Two cyclin D1-negative cases overexpressing cyclin D2 were detected by immunoblotting.
Conclusions: There are rare cyclin D1-negative cases of MCL overexpressing cyclin D2. Anti-cyclin D1 antibodies with low specificity can bind both cyclin D1 and cyclin D2, thus providing false cyclin D1-positive signals in immunohistochemical analysis.
Footnotes
-
Funding This work was supported by grants NR/9305-3 of IGA of Ministry of Health of the Czech Republic, MSM0021622415 of Ministry of Education, Youth and Sports of the Czech Republic, and 204/08/H054 of Grant Agency of the Czech Republic.
-
Competing interests None declared.
-
Ethics approval Ethics approval was obtained from the Ethics Committee of University Hospital Brno.
-
Provenance and peer review Not commissioned; externally peer reviewed.








